NLRP3 targeting antisense oligonucleotide therapeutic - Secarna Therapeutics
Latest Information Update: 11 Sep 2024
At a glance
- Originator Secarna Pharmaceuticals
- Class Antisense oligonucleotides; Cardiovascular therapies
- Mechanism of Action Gene silencing; NLRP3 protein expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders
- Research Metabolic disorders
Most Recent Events
- 09 Sep 2024 Preclinical trials in Cardiovascular disorders in Germany (Parenteral) before September 2024
- 09 Sep 2024 Pharmacodynamics data from a preclinical trial in Cardiovascular diseases released by Secarna Therapeutics
- 21 Dec 2023 Early research in Cardiovascular disorders in Germany (Parenteral) before December 2023 (Secarna Pharmaceuticals pipeline, December 2023)